Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-23-014273
Date:2023-02-27
Issuer: CRISPR THERAPEUTICS AG (CRSP)
Original Submission Date:

Reporting Person:

KULKARNI SAMARTH
C/O CRISPR THERAPEUTICS, INC.
105 W FIRST STREET BOSTON, MA 02127

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON SHARES 2023-02-27 M 25,000 a $19.12 400,988 direct
COMMON SHARES 2023-02-27 S 10,180 d $47.71 390,808 direct
COMMON SHARES 2023-02-27 S 13,720 d $48.57 377,088 direct
COMMON SHARES 2023-02-27 S 1,100 d $49.20 375,988 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 19.12 2023-02-27 deemed execution date M 25,000 (d) 2027-12-01 common shares 25,000 $19.12 154,582 direct
Footnotes
IDfootnote
f1 the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $47.13 to $48.07, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $48.13 to $49.11, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $49.1350 to $49.24, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range.
f5 this option was granted on december 1, 2017 with respect to 260,000 common shares with 100% of the shares vesting in 48 equal monthly installments beginning january 1, 2018.
WhaleWisdom Logo

Elevate your investments